All these suggest that targeted screening for COL1A1 expression should be focused on individuals of younger age (<66 years), and at the same time, those esophageal tumor patients with hyperglycemia or diabetes should be strengthened for COL1A1 gene screening. The gene discussed is COL1A1; the disease is Hyperglycemia.